Frederick K. Goodwin, M.D.; H. Keith; H. Brodie, M.D.
This content is PDF only. Please click on the PDF icon to access.
The purpose of this study is to provide a more direct evaluation of the hypothesis that depression is associated with a functional decrease in brain catecholamines. Since the amines themselves do not pass the blood brain barrier, L-3:4 dihydroxyphenylalanine (DOPA), the amino acid precursor of dopamine (DA) and norepinephrine (NE), was administered orally to depressed patients. The great majority of the DOPA is decarboxylated in the periphery, and, in addition, the barrier involving decarboxylation of DOPA to DA in the brain capillary wall is not overcome in animals until high doses of DOPA are achieved. In animals the use of
Learn more about subscription options.
Register Now for a free account.
Goodwin FK, Keith H, Brodie H. The Combined Use of L-DOPA and a Peripheral Decarboxylase Inhibitor (MK485) in Depression.. Ann Intern Med. 1970;72:806. doi: 10.7326/0003-4819-72-5-806_2
Download citation file:
Published: Ann Intern Med. 1970;72(5):806.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only